Aviat Networks has signed a license-to-manufacture agreement with Dixon Electro Appliances to produce selected WTM 4000 microwave products in India. This move allows Aviat to expand its presence in India's growing microwave infrastructure market by leveraging local manufacturing, reducing logistical issues like import delays, and supporting a local supply chain. Aviat retains intellectual property and continues providing software and services, aiming to meet an estimated demand of 250,000 microwave links in India over the next four years. This partnership enhances Aviat's growth potential and service quality in the region.
Aviat Networks' new manufacturing partnership in India is the subject here. For readers following the Technology sector, 87 of 150 US stocks rose and 63 fell on Pluang. Notable movers include RELY at USD 23.15 with a 6.34% gain, VNET at USD 5.44 up 6.04%, and APP at USD 284.41 also up 6.04%, as of Oct 06, 2026 01:21 WIB.
Revvity's stock has surged 56.1% year-to-date, outperforming its industry and the S&P 500, driven by an 11% organic revenue growth in diagnostics, especially in reproductive health and immunodiagnostics. Analysts from William Blair and Zacks have upg...
Levi Strauss & Co. is set to report its Q3 2026 earnings on October 7, with analysts forecasting adjusted earnings of $0.36 per share and revenue of $1.61 billion, marking a 4.5% increase year-over-year. Strong denim demand and growth in Europe, Asia...
On October 5, 2026, five notable stocks experienced double-digit declines. Sphere Entertainment fell 13.6% after a downgrade from Craig-Hallum, while C.H. Robinson dropped 10.9% following its announcement to acquire RXO for $5.8 billion. Velo3D, Boos...
Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...
Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...
